In recent times, molecular biomarkers such as Somatic mutations in the Xq13 gene that encodes the RNA Polymerase II (Pol II) mediator subunit MED12 are the most common, accounting for 45%–90% of uterine leiomyoma cases, with prevalence varying based on patient ethnicity (Mäkinen et al., 2011; Mehine et al., 2014). Here, MED12 is linked to uterine corpus leiomyoma.